Traders should monitor the FTC review process and shareholder voting results. The significant premium suggests limited downside risk, but regulatory uncertainty could create volatility. Boston Scientific shareholders may see temporary dilution from the stock component.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 2 $330.36entry
- T+1 · 8mo ago −0.15%α −0.62% · $329.87
- T+5 · 7mo ago −0.18%α −3.80% · $329.77
- T+20 · 7mo ago −1.17%α −11.05% · $326.48
- T+60 · 5mo ago −4.42%α −18.58% · $315.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Penumbra Inc is being acquired by Boston Scientific in a mixed cash-and-stock deal valued at $374.00 per share, representing a 26% premium to Penumbra's unaffected stock price. The Penumbra board unanimously recommends approval, citing strategic benefits from Boston Scientific's global scale. Regulatory approvals are pending, including a Second Request from the FTC, with closing expected in 2026.
Key Financial Metrics
Key Facts
- Deal valued at $374.00 per Penumbra share, combining cash ($374.00) and stock (3.8721 Boston Scientific shares) options for shareholders
- 26.74% of shares will receive stock consideration, 73.26% will receive cash, subject to proration
- Perella Weinberg Partners issued a fairness opinion supporting the deal's financial terms
- Boston Scientific will pay a $900 million termination fee if antitrust approvals are denied
- FTC issued a Second Request on March 16, 2026, extending the HSR waiting period
- Special meeting scheduled for May 6, 2026 for shareholder vote
Financial Impact
Approximately $14.7 billion total deal value based on 39.3 million shares outstanding and $374.00 per share price
Risk Factors
- Regulatory approval risk, particularly from FTC antitrust review
- Failure to obtain Penumbra shareholder approval
- Potential delays in closing beyond 2026
- Integration risks post-closing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001140361-26-012785 |
| Document: ny20065749x1_defm14a.htm | 0001140361-26-012785 |
Track record
11 reports on PEN
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +1.63% at T+20 after the May 6, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $321.46 Now $320.62 −0.26% settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $319.21 Now $320.62 +0.44% settles Feb 4
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Neutral 5/10 Entry $318.95 Now $320.62 +0.52% settles Jan 28
- Jul 30, 202615w ago Press Release Bearish 6/10 Entry $321.19 to $325.22 Now $320.62 +0.18% ▼ −1.25% +1.20% vs SPY
- May 7, 202627w ago 425 Bullish 7/10 Entry $324.65 to $323.02 Now $320.62 −1.24% ▼ −0.50% −4.34% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $324.65 to $323.02 Now $320.62 +1.24% ▲ +0.50% +4.34% vs SPY
- Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $326.48 to $319.49 Now $320.62 −1.79% ▼ −2.14% −5.25% vs SPY
- Apr 17, 202630w ago 425 Neutral 4/10 Entry $329.71 to $316.73 Now $320.62 −2.76% ▼ −3.94% −10.71% vs SPY
- Apr 1, 202632w ago DEFM14A Bullish 8/10 Viewing Entry $330.36 to $315.75 Now $320.62 −2.95% ▼ −4.42% −18.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers